Regeneron Pharmaceuticals, Inc. has announced five-year follow-up results from the Phase 3 EMPOWER-Lung 3 trial, evaluating Libtayo® (cemiplimab) in combination with platinum-based chemotherapy as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 aberrations. The results, which have already been presented at the IASLC 2025 World Conference on Lung Cancer, demonstrate that the combination treatment more than doubles the five-year overall survival rate to 19.4%, compared to 8.8% with chemotherapy alone. The study showed consistent efficacy across histologies, with a notable median overall survival of 22.3 months for the squamous patient population. Additionally, exploratory subgroup analyses indicated survival benefits regardless of tumor histology or PD-L1 expression levels.